Aduro Biotech, Inc. (NASDAQ:ADRO) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
Results of Operations and Financial Condition.
Aduro Biotech, Inc. (NASDAQ:ADRO) Files An 8-K Results of Operations and Financial Condition
On March 1, 2018, Aduro Biotech, Inc. (“Aduro”) announced certain financial results for its fourth quarter and year ended December 31, 2017. A copy of Aduro’s press release, titled “Aduro Biotech Announces Fourth Quarter and Full Year 2017 Financial Results,” is furnished to Item 2.02 as Exhibit 99.1 hereto.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
Exhibit |
Description |
|
99.1 |
Press Release, dated March 1, 2018, titled “Aduro Biotech Announces Fourth Quarter and Full Year 2017 Financial Results” |
The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Aduro Biotech, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.
EXHIBIT INDEX
ADURO BIOTECH, INC. ExhibitEX-99.1 2 adro-ex991_6.htm EX-99.1 adro-ex991_6.htm Exhibit 99.1 Contact: Media Contact: Jennifer Lew Aljanae Reynolds Chief Financial Officer 510-809-2452 510-809-4816 [email protected] Aduro Biotech Announces Fourth Quarter and Full Year 2017 Financial Results BERKELEY,…To view the full exhibit click here
About Aduro Biotech, Inc. (NASDAQ:ADRO)
Aduro Biotech, Inc. is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. Its LADD product candidates include CRS-207, ADU-623, ADU-741 and ADU-214. Its STING Activator product candidates include ADU-S100. Its LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Its STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. Its B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.
